OUTBACK Trial Reveals No Benefit for Adjuvant Chemotherapy in Cervical Cancer
Bradley Monk, MD, FACCOG, FACS, discusses the creation and findings of the OUTBACK trial.
Investigating Combinations in Recurrent or Metastatic Cervical Cancer
Bradley Monk, MD, discusses the phase 1b/2 innovaTV 205 trial in patients with recurrent or metastatic cervical cancer.
Trabectedin as a Treatment Option for Patients with Ovarian Cancer
Bradley Monk, MD, gynecologic oncologist, University of Arizona Cancer Center Phoenix Branch, discusses trabectedin as a potential agent to treat ovarian cancer.
Bevacizumab for Cervical Cancer
Bradley Monk, MD, gynecologic oncologist, University of Arizona Cancer Center Phoenix Branch, discusses the utility of bevacizumab for the treatment of cervical cancer.
Individualized Treatments and Clinical Trial Endpoints in Ovarian Cancer
Bradley Monk, MD, gynecologic oncologist, University of Arizona Cancer Center Phoenix Branch, discusses clinical trial endpoints and individualizing treatment in patients with ovarian cancer.
The Role of Bevacizumab in Treatment of Metastatic Cervical Cancer
Bradley Monk, MD, gynecologic oncologist, University of Arizona Cancer Center Phoenix Branch, discusses the role of bevacizumab in the treatment of metastatic cervical cancer.